Status:
ACTIVE_NOT_RECRUITING
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Collaborating Sponsors:
Y-mAbs Therapeutics
Conditions:
Melanoma
Neuroblastoma
Eligibility:
All Genders
3-90 years
Phase:
NA
Brief Summary
The purpose of this study is to find out how an antibody called Hu3F8 travels through the body and to tumors. Antibodies, like Hu3F8, are proteins that help attack tumors or fight infections. Antibodi...
Eligibility Criteria
Inclusion
- Patients with the diagnosis of neuroblastoma must meet both of the following criteria:
- Diagnosis confirmed by histological assessment by MSKCC Department of pathology or by the presence of BM metastases PLUS elevated urinary catecholamines
- Relapsed or refractory stage 4 disease or relapsed or refractory stage MYCN-amplified 2B or 3 disease.
- Patients with tumors other than neuroblastoma must meet both the following criteria:
- Have one of the following diagnoses (these tumors are known to express GD2 on cell surface):
- Melanoma
- Osteogenic sarcoma
- Leiomyosarcoma
- Ewing sarcoma
- Liposarcoma
- Fibrosarcoma
- Malignant fibrous histiocytoma
- Spindle cell sarcoma
- Small cell lung cancer
- Medulloblastoma metastatic to extracranial sites
- Paraganglioma
- Have refractory or relapsed or metastatic disease
- Patients with solid tumors with diagnoses OTHER than neuroblastoma or those listed above will be eligible if they meet both of the following criteria:
- Immunohistochemical demonstration of GD2 expression on cell surface (Tumor assessment by immunohistochemistry is required for this group of patients)
- Have refractory or relapsed disease or metastatic disease. All patients must have measurable or evaluable disease
- Age 3-90 years
- Prior treatment with anti-GD2 monoclonal antibody is permitted only if human anti-human antibody titer is ≤1300 assay developed by Dr. Nai-Kong Cheung.
- Negative serum pregnancy test in women of childbearing potential
- Women of child-bearing potential must be willing to practice an effective method of birth control while on study
- Signed informed consent indicating awareness of the investigational nature of this study.
Exclusion
- Existing major organ dysfunction \> grade 2, with the exception of myelosuppression (neutrophil count \> or = 500/μl and platelet count \> or = 25,000/μl are acceptable) and hearing loss.
- Acute life threatening infection
- Requirement for sedation for PET/CT scans
- Pregnant women or women who are breast-feeding.
- Inability to comply with protocol requirements.
- Hypersensitivity to potassium iodide or Lugols products
- Prior development of positive human antimouse antibody response (HAMA) or human antihuman antibody response (HAHA)
- Positive human anti-hu3F8 antibody titer.
Key Trial Info
Start Date :
November 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2026
Estimated Enrollment :
7 Patients enrolled
Trial Details
Trial ID
NCT02307630
Start Date
November 1 2014
End Date
November 1 2026
Last Update
December 4 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Sloan Kettering Cancer Center
New York, New York, United States, 10065